4.6 Article

Evodiamine as a novel antagonist of aryl hydrocarbon receptor

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2010.09.122

Keywords

Aryl hydrocarbon receptor; Evodiamine; Docking; Homology modeling; Antagonist

Funding

  1. National High Technology Research and Development Program (863 Program) of China [2008AA02Z440]
  2. National Basic Research Program of China [2005CB522602]
  3. National Natural Science Foundation of China [20902068]
  4. State Key Laboratory of Trauma, Burns, and Combined Injury [SKLZZ200802]

Ask authors/readers for more resources

Evodiamine, the major bioactive alkaloid isolated from Wu-Chu-Yu, has been shown to interact with a wide variety of proteins and modify their expression and activities. In this study, we investigated the interaction between evodiamine and the aryl hydrocarbon receptor (AhR). Molecular modeling results revealed that evodiamine directly interacted with the AhR. Cytosolic receptor binding assay also provided the evidence that evodiamine could interact with the AhR with the K-i value of 28.4 +/- 4.9 nM. In addition, we observed that evodiamine suppressed the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced nuclear translocation of the AhR and the expression of CYP1A1 dose-dependently. These results suggested that evodiamine was able to bind to the AhR as ligand and exhibit antagonistic effects. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available